Cimpress (CMPR) Q3 2026 Earnings Transcript

Cimpress posted strong Q3 results, with adjusted EBITDA up 11% year over year to $100.5 million and revenue up 12% reported, while raising FY2026 guidance to at least $465 million of adjusted EBITDA and at least $87 million of net income. Management also highlighted $11 million of annualized OpEx savings, two tuck-in acquisitions completed in April, and a new $200 million buyback authorization. Headwinds from weather, energy costs, and working-capital currency effects were present, but the call emphasized improving margins, stronger free cash flow in FY2027, and reaffirmed FY2028 targets.

Analysis

CMPR is transitioning from a “show me” deleveraging story to a self-funded compounding story, and that matters because the equity should re-rate when the market believes EBITDA can grow faster than working capital can consume cash. The biggest hidden positive is not the current quarter itself, but the widening gap between EBITDA growth and the capital intensity of the business: if the company really converts closer to the implied 45% FCF conversion in 2028, the stock stops trading like a levered industrial and starts behaving more like a software-enabled branded consumer platform with recurring operating leverage.

The market may be underestimating how accretive the recent tuck-ins are to competitive positioning, not just earnings. These deals deepen CMPR’s presence in offline, fragmented niches where scale purchasing, fulfillment density, and software integration can compress smaller competitors’ margins faster than the acquired revenue grows. That should create a second-order effect: the more CMPR standardizes production and procurement across businesses, the more it can selectively price up while preserving share, which is a far better long-term dynamic than volume-led growth alone.

The main risk is that the balance-sheet story still depends on timing assumptions that can look fine in aggregate but wobble quarter-to-quarter. FX, fuel, and working-capital reversals can all mask underlying execution, so the next 1-2 quarters matter less for the thesis than whether Q4 and early FY27 show cash conversion inflecting as promised. If that inflection slips, the market will likely treat the guidance bridge as financial engineering rather than durable operating leverage, and the multiple expansion case stalls.

Contrarian view: consensus may be too anchored on the 2028 target as a distant aspiration instead of an achievable near-mid-cycle run-rate. If FY27 EBITDA really clears 10% growth and working capital normalizes, the market could start discounting FY28 earlier than expected, especially if buybacks resume into any valuation weakness. The opportunity is to own the setup before cash flow evidence arrives, not after the leverage ratio is visibly below 2x.

Key Decisions for Investors

• Go long CMPR on a 3-6 month horizon ahead of Q4/FY27 cash conversion proof; thesis is 15-25% upside if the market starts capitalizing the 2028 bridge, with downside limited if leverage holds at or below 3.0x.
• For more convexity, buy CMPR Jan-2027 or Jan-2028 calls financed with a lower-strike call spread; this captures re-rating risk if the market revalues the 2028 EBITDA/FCF trajectory before the numbers fully print.
• Pair trade: long CMPR / short a basket of slower-growth, higher-leverage print-adjacent names or small-cap marketing services exposure over 6-12 months; CMPR has better operating leverage and a clearer deleveraging path.
• If already long, use any post-earnings strength to sell 1-2 quarter upside calls against the position; near-term upside is likely to be choppy around working-capital noise, while the fundamental story should continue improving into FY27.
• Avoid adding aggressively if leverage begins to drift above 3.0x or if Q4 free cash flow fails to rebound materially; that would be the earliest signal the market will de-rate the execution narrative.